CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases

Cases of interstitial lung disease and pneumonitis have been reported in patients receiving CDK4/6 inhibitors indicated for some breast cancers. Ensure that patients taking these medicines are aware of the need to seek …

Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)

Cases of severe cutaneous adverse reactions, including Stevens-Johnsons syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients treated with immune-stimulatory anti-cancer drugs, including atezoli…

COVID-19 vaccines: updates for June 2021

A summary of advice recently issued by the MHRA relating to coronavirus (COVID-19), up to 11 June 2021.

Letters and medicine recalls sent to healthcare professionals in May 2021

A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.

Posted on the UK MHRA website on 17 June 2021